Completed Hemophilia A trials in Ukraine: Trial Insights

Filters: Condition: Hemophilia A Status: Completed Country / region: Ukraine Clear all

33 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2009	2
2010	2
2011	1
2012	2
2013	6
2014	5
2015	4
2016	1
2017	2
2018	5
2019	2
2021	1

Trials by status
Category	Trials
Completed	33

Top lead sponsors
Category	Trials
Baxalta now part of Shire	9
Novo Nordisk A/S	7
CSL Behring	4
Genzyme, a Sanofi Company	4
Bayer	3
Octapharma	3
Pfizer	2
Laboratoire français de Fractionnement et de Biotechnologies	1

Top conditions
Category	Trials
Hemophilia A	33
Hemophilia B	7
Blood Coagulation Disorders	2
Blood Coagulation Disorders, Inherited	2
Coagulation Protein Disorders	2
Genetic Diseases, Inborn	2
Genetic Diseases, X-Linked	2
Hematologic Diseases	2
Hemorrhagic Disorders	2

Trials

Showing 1 to 25 of 33. Each trial links to its page on Pharma Observatory.

A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors NCT05053139Phase 3CompletedNovo Nordisk A/SStarted 2021
FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR) NCT02764489Phase 3CompletedBaxalta now part of ShireStarted 2019
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX NCT03754790Phase 3CompletedGenzyme, a Sanofi CompanyStarted 2019
A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6) NCT03741881ObservationalCompletedNovo Nordisk A/SStarted 2018
A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis NCT03549871Phase 3CompletedGenzyme, a Sanofi CompanyStarted 2018
A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A NCT03528551Phase 3CompletedNovo Nordisk A/SStarted 2018
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors NCT03417245Phase 3CompletedGenzyme, a Sanofi CompanyStarted 2018
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors NCT03417102Phase 3CompletedGenzyme, a Sanofi CompanyStarted 2018
Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A NCT03376516Phase 3CompletedOctapharmaStarted 2017
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors NCT03196297Phase 2CompletedNovo Nordisk A/SStarted 2017
LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures NCT02548143Phase 3CompletedLaboratoire français de Fractionnement et de BiotechnologiesStarted 2016
BAX 855 PK-guided Dosing NCT02585960Phase 3CompletedBaxalta now part of ShireStarted 2015
A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A NCT02615691Phase 3CompletedBaxalta now part of ShireStarted 2015
A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors NCT02571569Phase 1CompletedBayerStarted 2015
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects NCT02490787Phase 1CompletedNovo Nordisk A/SStarted 2015
BAX 855 Pediatric Study NCT02210091Phase 3CompletedBaxalta now part of ShireStarted 2014
An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A NCT02172950Phase 3CompletedCSL BehringStarted 2014
Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A NCT02137850Phase 3CompletedNovo Nordisk A/SStarted 2014
Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII NCT01992549Phase 3CompletedOctapharmaStarted 2014
Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A NCT02093897Phase 3CompletedCSL BehringStarted 2014
Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures NCT01913405Phase 3CompletedBaxalta now part of ShireStarted 2013
BAX 855 Continuation NCT01945593Phase 3CompletedBaxalta now part of ShireStarted 2013
Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients NCT01712438Phase 3CompletedOctapharmaStarted 2013
A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A NCT01731600Phase 3CompletedNovo Nordisk A/SStarted 2013
Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen NCT01757405Phase 3CompletedBaxalta now part of ShireStarted 2013

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory